CHART Thread, page-2689

complete dog of a stock last several months for sure. But far from a dog company! I’m sure I’m not the only one wishing he sold at the top in March, but at the same time, this company has great fundamentals that are ever improving, and eventually the price will converge with the strong fundamentals.

this is about as de risked as a biotech gets too with the strong phase 2 POC results for IHL-42x. That’s a massive opportunity and I think we just need to be patient.